Mallinckrodt plc (MNK) : The consensus on Mallinckrodt plc (MNK) based on 12 analyst recommendation on the company stock is 1.21, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 10 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Mallinckrodt plc (MNK) : Average target price received by Mallinckrodt plc (MNK) is $90.27 with an expected standard deviation of $11.52. The most aggressive target on the stock is $115, whereas the most downbeat target is $75. 11 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. Also, BMO Capital initiates coverage on Mallinckrodt plc (NYSE:MNK) The shares have been rated Outperform. The rating by the firm was issued on June 29, 2016.
Mallinckrodt plc (NYSE:MNK): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $77.15 and $76.43 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $81.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $79.66, notching a gain of 3.58% for the day. The total traded volume was 3,404,475 . The stock had closed at $76.91 on the previous day.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops, manufactures, markets and distributes both branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops, manufactures and sells, through its Brands business, drugs, including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide), a neonatal critical care product.